Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden · Delayed Price · Currency is SEK 1.032
+0.002 (0.19%)
Jul 24, 2026, 5:29 PM CET
Diamyd Medical AB Balance Sheet
Financials in millions SEK. Fiscal year is September - August.
Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Cash & Equivalents | 306.37 | 277.19 | 112.76 | 127.53 | 119.76 | 139.38 |
Short-Term Investments | 39.73 | - | 19.61 | - | 39.91 | - |
Cash & Short-Term Investments | 346.11 | 277.19 | 132.37 | 127.53 | 159.67 | 139.38 |
Cash Growth | 8.41% | 109.41% | 3.79% | -20.13% | 14.56% | 103.88% |
Accounts Receivable | 0.04 | - | 0.02 | 0.06 | 0.25 | 0.05 |
Other Receivables | 3.91 | 4.09 | 2.71 | 4 | 2.19 | 1.59 |
Total Trade Receivables | 3.94 | 4.09 | 2.73 | 4.06 | 2.45 | 1.65 |
Other Current Assets | 1.83 | 11.13 | 24.05 | 9.22 | 10.9 | 21.95 |
Total Current Assets | 352.18 | 292.4 | 159.14 | 140.81 | 173.01 | 162.97 |
Net Property, Plant & Equipment | 48.4 | 52.7 | 49.36 | 52.32 | 45.75 | 5.55 |
Other Intangible Assets | - | - | - | - | - | 0.07 |
Long-Term Investments | 5.91 | 7.25 | 7.9 | 10.57 | 15.46 | 32.22 |
Other Long-Term Assets | 0.14 | 0.28 | 0.64 | 2.11 | 2.3 | 0.63 |
Total Assets | 406.63 | 352.64 | 217.04 | 205.81 | 236.52 | 201.44 |
Accounts Payable | 7.11 | 11.96 | 16.61 | 4.89 | 9.78 | 5.57 |
Accrued Expenses | 7.88 | 7.61 | 14.5 | 5.54 | 5.03 | 4.79 |
Other Current Liabilities | 7.72 | 7.92 | 8.92 | 9.43 | 6.56 | 1.04 |
Total Current Liabilities | 22.72 | 27.48 | 40.03 | 19.85 | 21.37 | 11.4 |
Other Long-Term Liabilities | 195.83 | 45.27 | 31.51 | 17.25 | 1.55 | 0.78 |
Total Long-Term Liabilities | 195.83 | 45.27 | 31.51 | 17.25 | 1.55 | 0.78 |
Total Liabilities | 218.55 | 72.75 | 71.54 | 37.1 | 22.92 | 12.18 |
Common Stock | 15.72 | 13.95 | 10.11 | 8.7 | 7.8 | 7.26 |
Additional Paid-in Capital | 1,100 | 884.67 | 586.55 | 460.49 | 390.71 | 249.1 |
Retained Earnings | -855.9 | -618.62 | -450.74 | -299.79 | -184.13 | -67.1 |
Shareholders' Equity | 259.39 | 280 | 145.92 | 169.4 | 214.38 | 189.26 |
Total Liabilities & Equity | 406.63 | 352.64 | 217.04 | 205.81 | 236.52 | 201.44 |
Net Cash (Debt) | 346.11 | 277.19 | 132.37 | 127.53 | 159.67 | 139.38 |
Net Cash Growth | 24.86% | 109.41% | 3.79% | -20.13% | 14.56% | 103.88% |
Net Cash Per Share | 2.46 | 2.46 | 1.40 | 1.63 | 2.09 | 2.00 |
Book Value | 259.39 | 280 | 145.92 | 169.4 | 214.38 | 189.26 |
Book Value Per Share | 1.84 | 2.49 | 1.54 | 2.16 | 2.80 | 2.71 |
Tangible Book Value | 259.39 | 280 | 145.92 | 169.4 | 214.38 | 189.19 |
Tangible Book Value Per Share | 1.84 | 2.49 | 1.54 | 2.16 | 2.80 | 2.71 |